GGrantIndex
← Search

RECOMBINANT FACTOR VIII SQ IN PREVIOUSLY TREATED HEMOPHILIA A

$241M01FY2000RRNIH

University Of North Carolina Chapel Hill, Chapel Hill NC

Investigators

Linked publications & trials

Abstract

The purpose of this study is to assess the immediate and long-term safety and efficacy of on-demand treatment of patients with severe hemophilia A using recombinant factor VIII SQ (r-VIII SQ) over a one year period. Objective and subjective assessments of the product will be based on patient outcome, laboratory values, adverse event reports and the investigator's and patient's judgements.

View original record on NIH RePORTER →